JP2024149687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024149687A5 JP2024149687A5 JP2024129056A JP2024129056A JP2024149687A5 JP 2024149687 A5 JP2024149687 A5 JP 2024149687A5 JP 2024129056 A JP2024129056 A JP 2024129056A JP 2024129056 A JP2024129056 A JP 2024129056A JP 2024149687 A5 JP2024149687 A5 JP 2024149687A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/123108 WO2020132810A1 (en) | 2018-12-24 | 2018-12-24 | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| CNPCT/CN2018/123108 | 2018-12-24 | ||
| PCT/CN2019/127433 WO2020135335A1 (en) | 2018-12-24 | 2019-12-23 | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof |
| JP2021536788A JP7617633B2 (ja) | 2018-12-24 | 2019-12-23 | Ｃｄ１９及びｃｄ３と結合可能な多重特異性抗原結合タンパク質、ならびにその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536788A Division JP7617633B2 (ja) | 2018-12-24 | 2019-12-23 | Ｃｄ１９及びｃｄ３と結合可能な多重特異性抗原結合タンパク質、ならびにその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024149687A JP2024149687A (ja) | 2024-10-18 |
| JP2024149687A5 true JP2024149687A5 (enExample) | 2025-04-04 |
Family
ID=71126451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536788A Active JP7617633B2 (ja) | 2018-12-24 | 2019-12-23 | Ｃｄ１９及びｃｄ３と結合可能な多重特異性抗原結合タンパク質、ならびにその使用 |
| JP2024129056A Withdrawn JP2024149687A (ja) | 2018-12-24 | 2024-08-05 | Ｃｄ１９及びｃｄ３と結合可能な多重特異性抗原結合タンパク質、ならびにその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536788A Active JP7617633B2 (ja) | 2018-12-24 | 2019-12-23 | Ｃｄ１９及びｃｄ３と結合可能な多重特異性抗原結合タンパク質、ならびにその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220064295A1 (enExample) |
| EP (1) | EP3902840A4 (enExample) |
| JP (2) | JP7617633B2 (enExample) |
| CN (1) | CN113906054B (enExample) |
| AU (1) | AU2019412331A1 (enExample) |
| CA (1) | CA3124712A1 (enExample) |
| WO (2) | WO2020132810A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| EP3847196A4 (en) * | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| KR20250110243A (ko) * | 2022-11-01 | 2025-07-18 | 테네오투, 인크. | 비호지킨 림프종 치료 방법 |
| WO2024173830A2 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| SI2982696T1 (sl) * | 2008-11-07 | 2019-06-28 | Amgen Research (Munich) Gmbh | Zdravljenje akutne limfoblastne levkemije |
| CN107936121B (zh) * | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| CN104203981A (zh) | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| US20150017136A1 (en) * | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| EP2872170A4 (en) * | 2012-07-13 | 2016-06-22 | Zymeworks Inc | ASYMMETRIC BISPECIFIC HETERODIMERS WITH ANTI-CD3 CONSTRUCTS |
| EP3356407B1 (en) * | 2015-10-02 | 2021-11-03 | F. Hoffmann-La Roche AG | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
| US10870701B2 (en) * | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| CN108690138A (zh) * | 2017-04-12 | 2018-10-23 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用 |
| CN107903324B (zh) * | 2017-11-15 | 2021-01-29 | 北京绿竹生物技术股份有限公司 | 一种结合人cd19和cd3的双特异性抗体 |
-
2018
- 2018-12-24 WO PCT/CN2018/123108 patent/WO2020132810A1/en not_active Ceased
-
2019
- 2019-12-23 AU AU2019412331A patent/AU2019412331A1/en active Pending
- 2019-12-23 EP EP19902305.2A patent/EP3902840A4/en active Pending
- 2019-12-23 JP JP2021536788A patent/JP7617633B2/ja active Active
- 2019-12-23 WO PCT/CN2019/127433 patent/WO2020135335A1/en not_active Ceased
- 2019-12-23 CN CN201980091645.1A patent/CN113906054B/zh active Active
- 2019-12-23 CA CA3124712A patent/CA3124712A1/en active Pending
- 2019-12-23 US US17/417,480 patent/US20220064295A1/en active Pending
-
2024
- 2024-08-05 JP JP2024129056A patent/JP2024149687A/ja not_active Withdrawn